Affordable valved holding chamber that minimizes the technique and coordination needed for effective inhaler treatments.

The PARI VORTEX® is an affordable valved holding chamber that minimizes the technique and coordination needed for effective inhaler treatments. Designed with non-electrostatic technology, VORTEX® delivers 56% more respirable particles compared to traditional plastic holding chambers and spacers.1 Now patients of all ages are assured a more efficient and consistent medication dose from their MDI, resulting in optimal treatments and a better quality of life.

Configurations

Configuration Part # NDC # HCPCS #
VORTEX® Valved Holding Chamber 051F7000 83490-0510-35 A4627
VORTEX® with Chloe Ladybug 051F7100 83490-0510-37 A4627
VORTEX® with Felix Frog 051F7200 83490-0510-39 A4627

1Zuberhuhler P, et al. In vitro testing of new non-electrostatic holding chamber with hydrofluoralkane salbutamol and beclomethasone inhalers. CHEST 2002; 122:185S.
2Wildhaber JH, et al. Effects of electrostatic charge, flow delay and multiple actuations on the in vitro delivery of salbutamol from different small volume spacers for infants. Thorax 1996; 51:985-988.

The Difference is in the Delivery1

VORTEX significantly reduces oropharyngeal deposition, which may cause unwanted side effects, vs. MDI alone.

Throat Deposition Graph

VORTEX delivers a higher respirable drug dose than MDI alone and OptiChamber Diamond.

Fine Particle Dose Graph

1Measurements according to Ph. Eur. 2.9.18 and USP 601: Next Generation Impactor; const. flow 30l/min; 50 ± 5 % relative humidity and 23 ± 2 °C: 3 test devices each measured in triplicates (n=3×3=9); pMDI Sultanol® (100μg Salbutamol, GlaxoSmithKline);
* All registered marks and trademarks belong to their respective companies


Get this through Insurance